(RTTNews) - Oric Pharmaceuticals (ORIC), a clinical-stage biopharmaceutical company, reported new dose-optimisation results for its Rinzimetostat or ORIC-944 from the Phase Ib Study, and outlined plans to begin its first phase III registrational study in metastatic castration-res
1 views
Oric Pharma Unveils Rinzimetostat Phase Ib Data And Outlines Phase III Study In Prostate Cancer
(RTTNews) - Oric Pharmaceuticals (ORIC), a clinical-stage biopharmaceutical company, reported new dose-optimisation results for its Rinzimetostat or ORIC-944 from the Phase Ib Study, and outlined plans to begin its…
